Literature DB >> 23021241

Chapter two--Adenovirus strategies for tissue-specific targeting.

Matthew S Beatty1, David T Curiel.   

Abstract

Cancer gene therapy approaches have benefited greatly from the utilization of molecular-based therapeutics. Of these, adenovirus-based interventions hold much promise as a platform for targeted therapeutic delivery to tumors. However, a barrier to this progression is the lack of native adenovirus receptor expression on a variety of cancer types. As such, any adenovirus-based cancer therapy must take into consideration retargeting the vector to nonnative cellular surface receptors. Predicated upon the knowledge gained in native adenovirus biology, several strategies to transductionally retarget adenovirus have emerged. Herein, we describe the biological hurdles as well as strategies utilized in adenovirus transductional targeting, covering the progress of both adapter-based and genetic manipulation-based targeting. Additionally, we discuss recent translation of these targeting strategies into a clinical setting.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23021241      PMCID: PMC3664935          DOI: 10.1016/B978-0-12-398342-8.00002-1

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  131 in total

1.  Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.

Authors:  Sari Pesonen; Iulia Diaconu; Vincenzo Cerullo; Sophie Escutenaire; Mari Raki; Lotta Kangasniemi; Petri Nokisalmi; Gianpietro Dotti; Kilian Guse; Leena Laasonen; Kaarina Partanen; Eerika Karli; Elina Haavisto; Minna Oksanen; Aila Karioja-Kallio; Päivi Hannuksela; Sirkka-Liisa Holm; Satu Kauppinen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

Review 2.  The adenovirus capsid: major progress in minor proteins.

Authors:  Jort Vellinga; Stephanie Van der Heijdt; Rob C Hoeben
Journal:  J Gen Virol       Date:  2005-06       Impact factor: 3.891

3.  A quasi-atomic model of human adenovirus type 5 capsid.

Authors:  Céline M S Fabry; Manuel Rosa-Calatrava; James F Conway; Chloé Zubieta; Stephen Cusack; Rob W H Ruigrok; Guy Schoehn
Journal:  EMBO J       Date:  2005-04-21       Impact factor: 11.598

4.  Porcine adenovirus serotype 3 internalization is independent of CAR and alphavbeta3 or alphavbeta5 integrin.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Virology       Date:  2005-02-05       Impact factor: 3.616

5.  Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma.

Authors:  Miriam Böckmann; Matthias Drosten; Brigitte M Pützer
Journal:  J Gene Med       Date:  2005-02       Impact factor: 4.565

6.  Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.

Authors:  Anton V Borovjagin; Alexandre Krendelchtchikov; Nagarajan Ramesh; De-Chao Yu; Joanne T Douglas; David T Curiel
Journal:  Cancer Gene Ther       Date:  2005-05       Impact factor: 5.987

7.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.

Authors:  P Henning; K M E Andersson; K Frykholm; A Ali; M K Magnusson; P-A Nygren; O Granio; S S Hong; P Boulanger; L Lindholm
Journal:  Gene Ther       Date:  2005-02       Impact factor: 5.250

9.  Identification of sites in adenovirus hexon for foreign peptide incorporation.

Authors:  Hongju Wu; Tie Han; Natalya Belousova; Victor Krasnykh; Elena Kashentseva; Igor Dmitriev; Manjula Kataram; Parameshwar J Mahasreshti; David T Curiel
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.

Authors:  M K Magnusson; R Kraaij; R M Leadley; C M A De Ridder; W M van Weerden; K A J Van Schie; M Van der Kroeg; R C Hoeben; N J Maitland; L Lindholm
Journal:  Hum Gene Ther       Date:  2011-10-12       Impact factor: 5.695

View more
  32 in total

Review 1.  Gene therapy for radioprotection.

Authors:  W H Everett; D T Curiel
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

Review 2.  Development of gene therapy for blood disorders: an update.

Authors:  Arthur W Nienhuis
Journal:  Blood       Date:  2013-07-10       Impact factor: 22.113

Review 3.  Progress and problems with the use of suicide genes for targeted cancer therapy.

Authors:  Zahra Karjoo; Xuguang Chen; Arash Hatefi
Journal:  Adv Drug Deliv Rev       Date:  2015-05-22       Impact factor: 15.470

Review 4.  Advances in Alpha-1 Antitrypsin Gene Therapy.

Authors:  Reka Lorincz; David T Curiel
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

Review 5.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

Review 6.  Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.

Authors:  Paul Boucher; Xiaoxia Cui; David T Curiel
Journal:  J Control Release       Date:  2020-09-03       Impact factor: 9.776

Review 7.  Oncolytic Virotherapy: A Contest between Apples and Oranges.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2017-04-06       Impact factor: 11.454

Review 8.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

9.  "Double-punch" strategy for delivery of viral immunotherapy with prolonged tumor retention and enhanced transfection efficacy.

Authors:  Juan Wang; Chunqing Guo; Xiang-Yang Wang; Hu Yang
Journal:  J Control Release       Date:  2020-12-02       Impact factor: 9.776

Review 10.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.